Oppenheimer & Co. Inc. Takes Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Oppenheimer & Co. Inc. purchased a new stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 13,929 shares of the company’s stock, valued at approximately $156,000. Oppenheimer & Co. Inc. owned 0.05% of ClearPoint Neuro as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Essex Investment Management Co. LLC raised its stake in shares of ClearPoint Neuro by 0.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 463,853 shares of the company’s stock valued at $5,200,000 after acquiring an additional 1,267 shares during the period. Renaissance Technologies LLC raised its stake in shares of ClearPoint Neuro by 562.6% in the 2nd quarter. Renaissance Technologies LLC now owns 169,700 shares of the company’s stock valued at $915,000 after acquiring an additional 144,088 shares during the period. Legato Capital Management LLC raised its stake in shares of ClearPoint Neuro by 21.6% in the 2nd quarter. Legato Capital Management LLC now owns 158,968 shares of the company’s stock valued at $857,000 after acquiring an additional 28,227 shares during the period. AWM Investment Company Inc. purchased a new stake in ClearPoint Neuro during the 1st quarter worth approximately $894,000. Finally, Squarepoint Ops LLC purchased a new stake in ClearPoint Neuro during the 2nd quarter worth approximately $549,000. 30.08% of the stock is owned by hedge funds and other institutional investors.

ClearPoint Neuro Stock Up 6.7 %

Shares of CLPT opened at $11.84 on Friday. ClearPoint Neuro, Inc. has a fifty-two week low of $5.11 and a fifty-two week high of $14.13. The firm’s 50 day moving average price is $11.91 and its 200 day moving average price is $9.21. The company has a market cap of $326.47 million, a P/E ratio of -17.15 and a beta of 1.10.

Wall Street Analysts Forecast Growth

Separately, Lake Street Capital upped their target price on shares of ClearPoint Neuro from $11.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.